StockNews.com Begins Coverage on NovaBay Pharmaceuticals (NYSE:NBY)

Investment analysts at StockNews.com started coverage on shares of NovaBay Pharmaceuticals (NYSE:NBY) in a report released on Wednesday. The firm set a “hold” rating on the stock.

NovaBay Pharmaceuticals Trading Down 1.7 %

Shares of NBY opened at $0.56 on Wednesday. The firm has a market cap of $3.27 million, a P/E ratio of -0.01 and a beta of 0.73. NovaBay Pharmaceuticals has a 12 month low of $0.36 and a 12 month high of $9.08. The stock’s 50 day moving average is $0.63 and its two-hundred day moving average is $0.64.

NovaBay Pharmaceuticals Company Profile

NovaBay Pharmaceuticals, Inc, a biopharmaceutical company, develops and sells eyecare, skincare, and wound care products in the United States and internationally. It offers Avenova Spray, a solution for removing foreign materials, including microorganisms and debris from skin around the eye, such as the eyelid; and wound care products, which are used for cleansing and irrigation as part of surgical procedures, as well as treating certain wounds, burns, ulcers, and other injuries under the NeutroPhase and PhaseOne brands.